Notably, a next-generation SRC inhibitor that targets both catalytic activity and scaffolding function achieved more potent suppression of metastatic signaling and bone metastasis than conventional SRC inhibitors.<h4>Conclusions</h4>This study demonstrates that SRC plays distinct and essential roles in cancer cell motility, osteoclast activation, and immune evasion, which collectively drive breast cancer bone metastasis. Here, SRC is linked to breast carcinoma.